These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1812 related articles for article (PubMed ID: 32271377)

  • 1. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
    de Castro G; Rizvi NA; Schmid P; Syrigos K; Martin C; Yamamoto N; Cheng Y; Moiseyenko V; Summers Y; Vynnychenko I; Lee SY; Bryl M; Zer A; Erman M; Timcheva C; Raja R; Naicker K; Scheuring U; Walker J; Mann H; Chand V; Mok T;
    J Thorac Oncol; 2023 Jan; 18(1):106-119. PubMed ID: 36240972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
    Planchard D; Reinmuth N; Orlov S; Fischer JR; Sugawara S; Mandziuk S; Marquez-Medina D; Novello S; Takeda Y; Soo R; Park K; McCleod M; Geater SL; Powell M; May R; Scheuring U; Stockman P; Kowalski D
    Ann Oncol; 2020 May; 31(5):609-618. PubMed ID: 32201234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
    Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
    JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
    Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
    JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
    Garon EB; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; Robinet G; Le Moulec S; Natale R; Schneider J; Shepherd FA; Garassino MC; Geater SL; Szekely ZP; Van Ngoc T; Liu F; Scheuring U; Patel N; Peters S; Rizvi NA
    Clin Lung Cancer; 2021 Jul; 22(4):301-312.e8. PubMed ID: 33775558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
    Leighl NB; Laurie SA; Goss GD; Hughes BGM; Stockler M; Tsao MS; Hwang DM; Joubert P; Kulkarni S; Blais N; Joy AA; Mates M; Rana P; Yadav SK; Underhill C; Lee C; Bradbury PA; Hiltz A; Dancey J; Ding K; Vera-Badillo F;
    J Thorac Oncol; 2022 Mar; 17(3):434-445. PubMed ID: 34800700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
    Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
    Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
    Johnson ML; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Laktionov K; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Shi X; Poole L; Peters S; Garon EB; Mok T;
    J Clin Oncol; 2023 Feb; 41(6):1213-1227. PubMed ID: 36327426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
    Seiwert TY; Wildsmith S; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Baker V; Evans B; Morsli N; Jill Walker ; Real K; L'Hernault A; Psyrri A
    Cancer Immunol Immunother; 2024 Mar; 73(4):70. PubMed ID: 38430375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
    Tougeron D; Dahan L; Evesque L; Le Malicot K; El Hajbi F; Aparicio T; Bouché O; Bonichon Lamichhane N; Chibaudel B; Angelergues A; Bodere A; Phelip JM; Mabro M; Kaluzinski L; Petorin C; Breysacher G; Rinaldi Y; Zaanan A; Smith D; Gouttebel MC; Perret C; Etchepare N; Emile JF; Sanfourche I; Di Fiore F; Lepage C; Artru P; Louvet C;
    JAMA Oncol; 2024 Jun; 10(6):709-717. PubMed ID: 38573643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
    Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
    Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
    Paz-Ares L; Garassino MC; Chen Y; Reinmuth N; Hotta K; Poltoratskiy A; Trukhin D; Hochmair MJ; Özgüroğlu M; Ji JH; Statsenko G; Conev N; Bondarenko I; Havel L; Losonczy G; Xie M; Lai Z; Godin-Heymann N; Mann H; Jiang H; Shrestha Y; Goldman JW
    Clin Cancer Res; 2024 Feb; 30(4):824-835. PubMed ID: 37801329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
    Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
    Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.